Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil

被引：6
|
作者：
Tam, Constantine [1 ,2 ]
Kuss, Bryone [5 ,6 ]
Opat, Stephen [3 ,4 ]
Boulos, Joy [7 ]
Marlton, Paula [8 ,9 ]
机构：
[1] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia
[3] Monash Med Ctr, Dept Haematol, Melbourne, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Flinders Univ S Australia, Dept Haematol, Adelaide, SA, Australia
[6] Flinders Med Ctr, Adelaide, SA, Australia
[7] Roche Prod Ltd, Sydney, NSW, Australia
[8] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia
[9] Univ Queensland, Sch Med, Brisbane, Qld, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2017年 / 47卷
关键词：
anti-CD20; monoclonal antibody; rituximab; obinutuzumab; CLL; ILLNESS RATING-SCALE; NON-HODGKIN-LYMPHOMA; RITUXIMAB; TRIAL; CLL; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; REGIMEN;
D O I：
10.1111/imj.13493
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered unfit' for fludarabine-cyclophosphamide-rituximab therapy. In these patients, the combination of obinutuzumab-chlorambucil may be an appropriate therapeutic choice. Obinutuzumab-chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab-chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab-chlorambucil.
引用
收藏
页码：5 / 10
页数：6
相关论文
共 50 条
  • [1] Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia
    Gay, Nathan D.
    Kozin, Eliana
    Okada, Craig
    Danilov, Alexey V.
    Spurgeon, Stephen
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2258 - 2260
  • [2] Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
    Hill, Brian T.
    Kalaycio, Matt
    ONCOTARGETS AND THERAPY, 2015, 8 : 2391 - 2397
  • [3] Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial
    Knauf, Wolfgang U.
    Lissitchkov, Toshko
    Aldaoud, Ali
    Liberati, Anna M.
    Loscertales, Javier
    Herbrecht, Raoul
    Juliusson, Gunnar
    Postner, Gerhard
    Gercheva, Liana
    Goranov, Stefan
    Becker, Martin
    Fricke, Hans-Joerg
    Huguet, Francoise
    Del Giudice, Ilaria
    Klein, Peter
    Merkle, Karlheinz
    Montillo, Marco
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 159 (01) : 67 - 77
  • [4] OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL IN THE FIRST LINE OF TREATMENT OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Markova, E. E.
    Nikitin, E. A.
    Dmitrieva, E. A.
    Mayorova, S. Yu
    Kochkareva, Yu B.
    Naumova, E., V
    Lugovskaya, S. A.
    Pochtar, M. E.
    Petrenko, A. A.
    Kislova, M., I
    Biderman, B., V
    Sudarikov, A. B.
    Obukhova, T. N.
    Ptushkin, V. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2022, 67 (04): : 478 - 490
  • [5] Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
    Hillmen, Peter
    Robak, Tadeusz
    Janssens, Ann
    Babu, K. Govind
    Kloczko, Janusz
    Grosicki, Sebastian
    Doubek, Michael
    Panagiotidis, Panagiotis
    Kimby, Eva
    Schuh, Anna
    Pettitt, Andrew R.
    Boyd, Thomas
    Montillo, Marco
    Gupta, Ira V.
    Wright, Oliver
    Dixon, Iestyn
    Carey, Jodi L.
    Chang, Chai-Ni
    Lisby, Steen
    McKeown, Astrid
    Offner, Fritz
    LANCET, 2015, 385 (9980) : 1873 - 1883
  • [6] A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Tedeschi, Alessandra
    Greil, Richard
    Demirkan, Fatih
    Robak, Tadeusz
    Moreno, Carol
    Barr, Paul M.
    Anz, Bertrand
    Simpson, David
    Gaidano, Gianluca
    Bairey, Osnat
    Stevens, Don
    Gill, Devinder
    Flinn, Ian W.
    Kipps, Thomas J.
    Burger, Jan A.
    Lin, Jennifer
    Webb, Thomas
    Fedorov, Viktor
    Styles, Lori
    Gribben, John G.
    HAEMATOLOGICA, 2020, 105 (04)
  • [7] Phase 2, multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia
    Sharman, Jeff P.
    Burke, John M.
    Yimer, Habte A.
    Boxer, Michael A.
    Babu, Sunil
    Li, Jia
    Mun, Yong
    Danilov, Alexey V.
    LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 791 - 800
  • [8] Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
    Knauf, Wolfgang U.
    Lissichkov, Toshko
    Aldaoud, Ali
    Liberati, Anna
    Loscertales, Javier
    Herbrecht, Raoul
    Juliusson, Gunnar
    Postner, Gerhard
    Gercheva, Liana
    Goranov, Stefan
    Becker, Martin
    Fricke, Hans-Joerg
    Huguet, Francoise
    Del Giudice, Ilaria
    Klein, Peter
    Tremmel, Lothar
    Merkle, Karlheinz
    Montillo, Marco
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4378 - 4384
  • [9] Pentostatin and Rituximab Therapy for Previously Untreated Patients With B-Cell Chronic Lymphocytic Leukemia
    Kay, Neil E.
    Wu, Wenting
    Kabat, Brian
    LaPlant, Betsy
    Lin, Thomas S.
    Byrd, John C.
    Jelinek, Diane F.
    Greyer, Michael R.
    Zent, Clive S.
    Call, Timothy G.
    Shanafelt, Tait D.
    CANCER, 2010, 116 (09) : 2180 - 2187
  • [10] Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective
    Owen, Carolyn J.
    Stewart, Douglas A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (04) : 161 - 170
12345